Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG Glycomine, Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapies for patients suffering from orphan and underserved diseases, has announced the successful closure of a…
Flatiron Health Partners with Veeva to Advance Oncology Research In a significant development for the digital health and clinical research sectors, Flatiron Health—a pioneer in healthtech focused on transforming clinical research—has announced a new strategic partnership with Veeva Systems, a…
Octave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions In a significant advancement for the field of neurodegenerative disease management, Octave Bioscience, Inc., a precision care company focused on transforming how multiple sclerosis (MS) and other…
Eyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial Bangalore-based biotech firm Eyestem Research has reported highly encouraging results from its Phase 1 clinical trial evaluating Eyecyte-RPE™, a novel investigational cell therapy aimed at treating geographic atrophy (GA) secondary…
Aulos Bioscience Begins Phase 2 Dosing of AU-007 and Nivolumab Combo for Melanoma Immuno-oncology innovator Aulos Bioscience has initiated dosing in a new cohort of its ongoing Phase 1/2 clinical trial, marking a significant step forward in the development of…
New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation Reduction Act (IRA) on the U.S. biopharmaceutical sector—particularly in the…
Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced a significant milestone today in its ongoing Phase 2 clinical…
Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet medical needs, announced significant updates today regarding its lead investigational…
Biologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients Landmark Clinical Trial Finds Certolizumab Significantly Improves Pregnancy Outcomes in Women with Antiphospholipid Syndrome In a groundbreaking advancement for maternal-fetal medicine and autoimmune disease treatment, a phase 2 clinical trial co-led…
Two Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients In a significant advancement for infectious disease care and antibiotic stewardship, two large-scale clinical trials funded by the National Institutes of Health (NIH) have demonstrated that integrating real-time,…
Amylyx Begins Dosing in Phase 1 LUMINA Trial of AMX0114 for ALS Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a biopharmaceutical company dedicated to the development of innovative treatments for neurodegenerative diseases, has announced a significant milestone in its mission to combat…
NexThera Begins U.S. Trial with First Patient Dosed for Wet AMD Eye Drop NT-101 NexThera Co., Ltd., a biotechnology company at the forefront of ophthalmic innovation, announced a pivotal milestone in its drug development journey: the initiation of a Phase…